Conn.’s positive test rates rise again
Here are the most important things to know about COVID-19 in Connecticut.
Positive tests continues to grow in Connecticut
The percent of total tests that were positive in Connecticut continued to grow Thursday — 1.85 percent of all coronavirus tests in the state came back positive, up from 1.78 the previous day. Again, three more deaths from the virus were identified, and another three people were fighting the disease in the hospital, according to the state
Who should get a vaccine first? Health care professionals
A study on JAMA Network Open asked members of the public who they thought should get a vaccine first when one is available. Most people thought health care professionals should get a vaccine first. The goal is not only to better allocate limited resources but to build a little trust. “Public engagement can contribute to resource allocation decisions,” the study’s authors said. “Incorporating public preferences could advance the perceived legitimacy of vaccine allocation guidelines.”
Vaccine trial participants experience symptoms in Phase 3
Participants in the vaccine trial being managed by Moderna and AstraZenica reported symptoms like fever, body aches, headaches and exhaustion, and while the symptoms were described as intense by some patients, they tended to abate in a single day or less, as CNBC reported. The Moderna vaccine candidate is one of of four in Phase 3 trials in the United States.
Fauci says vaccine trials need a diverse group of patients
National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci told Congress that vaccine trials need to include a diverse group of patients. We need to get a diverse representation of the population in the clinical trials," he told a panel of Congressional Hispanic Caucus (CHC) members, as The Hill reported. "So when they are proven to be safe and effective, we can say they are safe and effective in everyone, not only in whites."
FDA looks into a wider scope of side effects from AstraZenica vaccine candidate
The FDA is widening the scope of its investigation into possible side effects from the AstraZenica vaccine candidate, probably resulting in further delays, as Reuters reported. The stage three trial has been on hold since Sept. 8, after a patient in the trial developed a spinal cord illness called transverse myelitis.